Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a moderate growth ranking despite weaker trends across all timeframes, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which viewed the hemp-derived product segment as a key entry point into the U.S. market [8].

Core Viewpoint - Four cannabis stocks are showing significant technical momentum despite new regulatory challenges from Washington, particularly a provision in a government funding bill that could re-criminalize many hemp-derived THC products [1][2]. Group 1: Stock Performance - The stocks demonstrating gains include Tilray Brands Inc. (NASDAQ:TLRY), Cronos Group Inc. (NASDAQ:CRON), Organigram Global Inc. (NASDAQ:OGI), and SNDL Inc. (NASDAQ:SNDL) [2]. - Benzinga Edge's Stock Rankings indicate that all four companies exhibit strong positive momentum, particularly over the last six months [3]. - The six-month returns for the stocks are as follows: TLRY at 156.82%, CRON at 20.39%, OGI at 26.23%, and SNDL at 32.81% [4]. Group 2: Individual Stock Analysis - TLRY shows a weaker price trend in the short term but strong trends in medium and long terms, with a pre-market decline of 1.77% [6]. - CRON maintains a weaker short-term price trend but strong medium and long-term trends, with a pre-market increase of 3.63% [6]. - OGI has a weaker price trend in the short and medium terms but a strong long-term trend, with a pre-market decline of 1.95% [6]. - SNDL has a weaker price trend across all timeframes but a moderate growth ranking, with a pre-market increase of 2.35% [6]. Group 3: Regulatory Environment - A new legislative provision in the funding package re-criminalizes intoxicating hemp products, which could significantly impact the market [7]. - Senator Rand Paul criticized the provision, stating it could eliminate nearly 100% of legal hemp products overnight, adversely affecting farmers [7]. - The regulatory changes may benefit multi-state operators by reducing "gray-market" competition but are expected to negatively impact Canadian companies like Tilray, which had aimed to enter the U.S. market through hemp-derived products [8].

Core Insights - The Canadian cannabis market is crucial for the global marijuana industry, with U.S. legalization efforts expected to drive growth and cross-border opportunities [1][15] - Leading Canadian cannabis stocks are gaining investor attention due to improving financials and international expansion, particularly Cronos Group, Aurora Cannabis, and OrganiGram [2][15] Industry Overview - The U.S. cannabis industry is projected to exceed $56 billion by 2030, driven by expanding state programs and rising consumer acceptance [1] - Discussions around federal reclassification and potential legalization are creating optimism in both Canadian and American markets [1] Company Summaries Cronos Group - Cronos Group operates several global brands and has an indirect presence in the U.S. through a partnership with PharmaCann, which operates over twenty dispensaries [3][6] - The company exited the U.S. CBD market in 2023 to focus on higher-margin international products, improving operational efficiency and long-term growth potential [3][6] - Financially, Cronos reported steady revenue growth in 2024, reduced operating losses, and a strong balance sheet supported by Altria Group [6][8] Aurora Cannabis - Aurora Cannabis is a leader in the global cannabis sector with large-scale cultivation facilities and a focus on medical and recreational products [8][10] - The company has positioned itself for U.S. market entry upon federal legalization and has a strong international presence in Europe, Australia, and South America [8][10] - Aurora achieved revenue growth in 2025, positive gross margins, and a small net income after years of losses, reflecting a notable financial recovery [10] OrganiGram Holdings - OrganiGram is recognized for its agility and rapid growth, enhancing its international presence through partnerships and the recent acquisition of Motif Labs [11][13] - The company achieved record quarterly revenues and positive adjusted EBITDA in 2025, driven by strong sales of premium products and improved production efficiency [13] - OrganiGram's focus on higher-margin segments and global export potential continues to attract investor interest, with positive trends in its financial performance [13][14]

Core Insights - Organigram Global Inc. has launched a new brand called happly, targeting consumers interested in 'mindful recreation' with THC products [1] - This launch marks the company's third U.S. hemp-derived delta-9 brand, expanding its presence in the U.S. hemp-derived THC market [1] Company Developments - Organigram is recognized as Canada's leading cannabis company by market share [1] - The introduction of happly follows the company's previous entry into the U.S. market with its Collective Project sparkling juices [1]

Core Insights - The article provides a market analysis of several cannabis companies, including Canopy Growth Corp, OrganiGram Holdings Inc, Aurora Cannabis Inc, and cbdMD Inc, highlighting their performance and market trends [1] Company Summaries - **Canopy Growth Corp**: The company has shown significant fluctuations in its stock price, reflecting broader market trends in the cannabis industry [1] - **OrganiGram Holdings Inc**: This company has been focusing on expanding its product offerings and improving operational efficiencies to enhance profitability [1] - **Aurora Cannabis Inc**: Aurora has been navigating challenges related to regulatory changes and market competition, impacting its growth strategy [1] - **cbdMD Inc**: cbdMD is positioning itself in the CBD market, emphasizing brand recognition and product quality to capture consumer interest [1] Industry Trends - The cannabis industry is experiencing increased competition, with companies striving to differentiate themselves through product innovation and branding [1] - Regulatory changes continue to shape the market landscape, influencing operational strategies and investment opportunities within the sector [1] - Consumer preferences are shifting towards high-quality and diverse product offerings, prompting companies to adapt their strategies accordingly [1]

Core Viewpoint - Organigram Global Inc (NASDAQ: OGI) shares are experiencing a significant increase due to renewed optimism in the cannabis sector following a social media post from former President Donald Trump promoting the health benefits of cannabis and hinting at potential changes in federal drug policy [1][2]. Company Overview - Organigram is a major Canadian cannabis producer with a diverse portfolio of recreational cannabis brands, including SHRED, Edison Cannabis Co., and Trailblazer [2]. - The company has expanded its e-commerce platform for hemp-derived THC beverages into 25 U.S. states, enhancing its market access and potential for growth [2]. Market Performance - As of the publication time, Organigram shares were up 15.09%, trading at $1.94 [3].

Group 1 - The U.S. industrial hemp sector showed strong performance on Monday, with notable gains in several companies [1] - Tilray (TLRY.US) increased by over 8.9%, OrganiGram Holdings (OGI.US) rose by more than 6%, and Sundial Growers (SNDL.US) climbed nearly 4% [1] - Aurora Cannabis (ACB.US) saw an increase of over 2.6%, while Canopy Growth (CGC.US) surged by more than 6.5% [1]

Group 1 - The cannabis sector is experiencing renewed interest due to President Trump's confirmation of an impending decision on marijuana rescheduling [1] - The decision is expected to be made within the coming weeks, which could significantly impact the industry [1] Group 2 - The article emphasizes the potential investment opportunities in undervalued companies within the cannabis sector [1] - The author's background in financial markets and institutions supports a thorough analysis of financial statements and market trends [1]

Company Performance - OrganiGram reported a quarterly loss of $0.03 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.01, marking an earnings surprise of -200.00% [1] - The company posted revenues of $51.16 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 5.86%, and showing a significant increase from $30.01 million in the same quarter last year [2] - Over the last four quarters, OrganiGram has not surpassed consensus EPS estimates, but it has topped consensus revenue estimates three times [2] Stock Performance - OrganiGram shares have declined approximately 1.2% since the beginning of the year, contrasting with the S&P 500's gain of 9.6% [3] - The current Zacks Rank for OrganiGram is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.01 on revenues of $49.86 million, and for the current fiscal year, it is $0.07 on revenues of $170.56 million [7] - The trend of estimate revisions for OrganiGram was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - The Medical - Products industry, to which OrganiGram belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact the stock's performance [8] - The top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

Financial Data and Key Metrics Changes - In Q3 fiscal 2025, gross sales increased by 73% year over year and 7.2% sequentially, reaching a record $110.2 million [28] - Net revenue also reached a record high, growing 72% year over year and 7.9% sequentially to $70.8 million [28] - Adjusted EBITDA for the quarter was $5.7 million, a 64% increase year over year [34] - Net loss for the quarter was $6.3 million compared to net income of $2.8 million in the prior year period [35] - Cash flow from operations was $14.6 million, a significant improvement from cash used of $3.7 million in the prior year [35] Business Line Data and Key Metrics Changes - Organigram maintained its position as the number one licensed producer in Canada with an 11.6% market share, leading in pre-rolls and vapes [7] - In the vape segment, Organigram held a 20.4% market share, while in the pre-roll segment, it held 8.3% [7] - The company achieved its highest edibles market share of 18.2% in the last twelve months [11] - International revenue reached $7.4 million, a 208% year over year increase [22] Market Data and Key Metrics Changes - The Canadian recreational cannabis market grew by 6.6% year over year, reaching $1.4 billion in retail sales [7] - Organigram's market share in flower increased to 10.6%, up 60 basis points from Q2 [7] - The beverage market share held by Organigram was 6.2% as of June [12] Company Strategy and Development Direction - The company is focused on balancing domestic and international market demands while expanding its product offerings [27] - Organigram is enhancing its operational capacity and efficiency, with significant investments in its facilities [16][20] - The company is optimistic about the long-term potential of the cannabis beverage market, especially with favorable regulatory changes in Canada [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a gross margin of approximately 35% for the full year, driven by seasonal throughput and synergies from the Motif acquisition [41][43] - The company remains cautious about shifting too much supply to international markets at the expense of domestic brands [29] - Management highlighted ongoing improvements in operational efficiency and the potential for margin expansion in the coming quarters [34][31] Other Important Information - The company is awaiting EU GMP certification, which is expected to enhance international sales and margins [26][56] - Management noted that approximately 27% of Moncton's harvest was seed-based, contributing to lower production costs [26] Q&A Session Summary Question: Outlook on gross margins and expected expansion - Management confirmed the expectation of a 35% average gross margin for the year, driven by seasonal throughput and synergies from the Motif acquisition [41][43] Question: Cultivation capacity and balancing domestic vs international demand - Management discussed ongoing capacity expansion projects and the reevaluation of previous investment plans to optimize production for both domestic and international markets [45][48] Question: Timing and impact of EU GMP certification - Management indicated that while the timing of the certification is uncertain, it will significantly enhance margins and reduce delays in product delivery [56][58] Question: Investment opportunities in the U.S. and potential federal reform - Management expressed excitement about the U.S. market but emphasized that current focus remains on international markets due to existing legal frameworks [66][67]